Search Results - "Fullenwider, Cody"

Characterization of Correction Factors to Enable Assessment of Clinical Risk from In Vitro CYP3A4 Induction Data and Basic Drug-Drug Interaction Models by Ramsden, Diane, Fullenwider, Cody L.

“…Background and Objective Induction of drug-metabolizing enzymes can lead to drug-drug interactions (DDIs); therefore, early assessment is often conducted…”
Get full text

Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model by Ramsden, Diane, Perloff, Elke S, Whitcher-Johnstone, Andrea, Ho, Thuy, Patel, Reena, Kozminski, Kirk D, Fullenwider, Cody L, Zhang, J George

“…Inactivation of Cytochrome P450 (CYP450) enzymes can lead to significant increases in exposure of comedicants. The majority of reported in vitro to in vivo…”
Get full text

Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes by Hutzler, J Matthew, Yang, Young-Sun, Albaugh, Daniel, Fullenwider, Cody L, Schmenk, Jennifer, Fisher, Michael B

“…Substrates of aldehyde oxidase (AO), for which human clinical pharmacokinetics are reported, were selected and evaluated in pooled mixed-gender cryopreserved…”
Get full text

Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems by Albaugh, Daniel R, Fullenwider, Cody L, Fisher, Michael B, Hutzler, J Matthew

“…The current studies assessed the utility of freshly plated hepatocytes, cryopreserved plated hepatocytes, and cryopreserved plated HepaRG cells for the…”
Get full text

Biopharmaceutics Permeability Classification of Lorcaserin, a Selective 5‑Hydroxytryptamine 2C Agonist: Method Suitability and Permeability Class Membership by Chen, Chuan, Ma, Michael G, Fullenwider, Cody L, Chen, Weichao G, Sadeque, Abu J. M

“…The objectives of the study were (1) to demonstrate that a Caco-2 cell-based permeability assay, developed in our laboratory, is suitable to identify the…”
Get full text

Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: Optimization of drug-like properties and target independent parameters by Zindell, Renée, Walker, Edward R., Scott, John, Amouzegh, Patricia, Wu, Lifen, Ermann, Monika, Thomson, David, Fisher, Micheal B., Fullenwider, Cody Lee, Grbic, Heather, Kaplita, Paul, Linehan, Brian, Patel, Mita, Patel, Monica, Löbbe, Sabine, Block, Svenja, Albrecht, Claudia, Gemkow, Mark J., Shih, Daw-Tsun, Riether, Doris

“…A high throughput screening campaign identified aryl 1,4-diazepane compounds as potent and selective cannabinoid receptor 2 agonists as compared to cannabinoid…”
Get full text

P144 - Mechanistic insights into the human ADME of a therapeutic candidate by Aloysius, Herve, Turski, Megan, Bowlin, Steve, Fullenwider, Cody, Kamel, Amin

Get full text

Design and Discovery of a Potent and Selective Inhibitor of Integrin αvβ1 by Sabat, Mark, Carney, Daniel W., Hernandez-Torres, Gloria, Gibson, Tony S., Balakrishna, Deepika, Zou, Hua, Xu, Rui, Chen, Chien-Hung, de Jong, Ron, Dougan, Douglas R., Qin, Ling, Bigi-Botterill, Simone V., Chambers, Alison, Miura, Joanne, Johnson, Lucas K., Ermolieff, Jacques, Johns, Deidre, Selimkhanov, Jangir, Kwok, Lily, DeMent, Kevin, Proffitt, Chris, Vu, Phong, Lindsey, Erick A., Ivetac, Tony, Jennings, Andy, Wang, Haixia, Manam, Padma, Santos, Cipriano, Fullenwider, Cody, Manohar, Rohan, Flick, Andrew C.

“…Selective inhibition of the RGD (Arg-Gly-Asp) integrin αvβ1 has been recently identified as an attractive therapeutic approach for the treatment of liver…”
Get full text